AAV Vector Gene Therapy for Lipodystrophy Adipose Restoration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Lipodystrophy, characterized by the absence or dysfunction of adipose tissue, leads to metabolic disorders such as diabetes and fatty liver disease due to lipid accumulation in ectopic sites, for which current treatments are inadequate.
Innovation Solution
Administration of a recombinant adenovirus-associated virus (AAV) vector containing a heterologous nucleic acid that encodes a functional version of a defective gene or an RNA molecule to inhibit defective gene expression, promoting adipose tissue restoration and metabolic function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If viral mediated gene therapy is administered to restore adipose tissue in lipodystrophy patients, then metabolic function is improved and adipose tissue is restored, but the complexity of the treatment increases and delivery challenges arise
Solution Approach 1:
The patent uses viral vectors as intermediary carriers to deliver therapeutic nucleic acids into target cells. The viral vector acts as a mediator that facilitates gene delivery by entering cells and releasing the therapeutic gene, thereby restoring adipose tissue function without requiring complex external delivery systems
Solution Approach 2:
The therapeutic approach enables self-service by having the patient's own cells produce the defective protein through the introduced functional gene. The body's cellular machinery automatically transcribes and translates the delivered nucleic acid, eliminating the need for continuous external intervention or complex delivery infrastructure
2Reliability
If a heterologous nucleic acid is introduced to encode a functional gene product, then the defective gene expression is corrected, but the risk of immune response and off-target effects increases
Solution Approach 1:
The patent employs tissue-specific promoters to drive expression of the therapeutic gene only in target tissues such as adipose tissue. This localized expression approach ensures that the functional protein is produced where needed while minimizing exposure of other tissues to foreign nucleic acids, thereby reducing immune response risk
Solution Approach 2:
The patent utilizes the natural tropism of viral vectors for specific cell types to achieve targeted gene delivery. What could be considered a harmful property of viruses (their ability to infect specific cells) is converted into a beneficial feature for selective therapeutic gene delivery to adipose tissue while sparing other organs
Data Source
AI summary
This invention relates to the restoration of adipose tissue inpatients with lipodystrophy characterised by a defective gene. A heterologous nucleic acid that encodes a therapeutic gene product is administered to the patient. The therapeutic gene product may be functional version of the protein encoded by the defective gene or an RNA molecule that inhibits expression from the defective gene. Methods for the treatment of lipodystrophy and the amelioration of metabolic dysfunction associated with lipodystrophy are provided, along with agents and compositions for use in such methods.